DK3362569T3 - Cxcr6-transducerede t-celler til målrettet tumorterapi - Google Patents
Cxcr6-transducerede t-celler til målrettet tumorterapi Download PDFInfo
- Publication number
- DK3362569T3 DK3362569T3 DK16793764.8T DK16793764T DK3362569T3 DK 3362569 T3 DK3362569 T3 DK 3362569T3 DK 16793764 T DK16793764 T DK 16793764T DK 3362569 T3 DK3362569 T3 DK 3362569T3
- Authority
- DK
- Denmark
- Prior art keywords
- cxcr6
- transduced
- cells
- tumor therapy
- targeted tumor
- Prior art date
Links
- 102100025618 C-X-C chemokine receptor type 6 Human genes 0.000 title 1
- 101000856683 Homo sapiens C-X-C chemokine receptor type 6 Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464421—Receptors for chemokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15190179 | 2015-10-16 | ||
PCT/EP2016/074644 WO2017064222A1 (en) | 2015-10-16 | 2016-10-14 | Cxcr6-transduced t cells for targeted tumor therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3362569T3 true DK3362569T3 (da) | 2021-10-18 |
Family
ID=54359823
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16793764.8T DK3362569T3 (da) | 2015-10-16 | 2016-10-14 | Cxcr6-transducerede t-celler til målrettet tumorterapi |
Country Status (8)
Country | Link |
---|---|
US (1) | US11723922B2 (da) |
EP (1) | EP3362569B1 (da) |
JP (2) | JP7018387B2 (da) |
AU (2) | AU2016336868B2 (da) |
CA (1) | CA3001507C (da) |
DK (1) | DK3362569T3 (da) |
ES (1) | ES2895901T3 (da) |
WO (1) | WO2017064222A1 (da) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018223211A1 (en) * | 2017-02-21 | 2019-10-10 | The University Of Adelaide | T cells expressing chemokine receptors for treating cancer |
US11655306B2 (en) | 2017-04-05 | 2023-05-23 | Korea Research Institute Of Bioscience And Biotechnology | NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same |
US20210002609A1 (en) * | 2017-12-05 | 2021-01-07 | Caribou Biosciences, Inc. | Modified lymphocytes |
US20210130438A1 (en) * | 2019-10-28 | 2021-05-06 | The Broad Institute, Inc. | Pan-cancer t cell exhaustion genes |
CN113736740A (zh) * | 2021-07-27 | 2021-12-03 | 天津市肿瘤医院(天津医科大学肿瘤医院) | 胰腺癌稳转细胞系及其构建方法和应用 |
WO2023158997A2 (en) * | 2022-02-15 | 2023-08-24 | Memorial Sloan-Kettering Cancer Center | Compositions including killer innate-like t cells and uses therof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6696244B2 (en) | 1997-07-17 | 2004-02-24 | New York University | G-coupled receptors associated with retroviral entry into cells, and therapeutic uses thereof |
DE19822115B4 (de) | 1998-05-08 | 2004-04-08 | Heinrich-Pette-Institut | Retrovirale Gentransfervektoren |
US8003770B2 (en) | 2005-09-13 | 2011-08-23 | Mie University | T-cell receptor and nucleic acid encoding the receptor |
US20110280894A1 (en) | 2008-07-31 | 2011-11-17 | Angela Krackhardt | Her2/neu specific t cell receptors |
CN107699585A (zh) | 2010-12-09 | 2018-02-16 | 宾夕法尼亚大学董事会 | 嵌合抗原受体‑修饰的t细胞治疗癌症的用途 |
US9266960B2 (en) | 2011-04-08 | 2016-02-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer |
AU2012325915A1 (en) | 2011-10-20 | 2014-04-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD22 chimeric antigen receptors |
AU2013235726B2 (en) | 2012-03-23 | 2017-04-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-mesothelin chimeric antigen receptors |
KR20220029757A (ko) | 2012-04-11 | 2022-03-08 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | B-세포 성숙 항원을 표적화하는 키메라 항원 수용체 |
US9657105B2 (en) | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
US10808035B2 (en) | 2013-08-26 | 2020-10-20 | Markus Chmielewski | Anti CD30 chimeric antigen receptor and its use |
-
2016
- 2016-10-14 EP EP16793764.8A patent/EP3362569B1/en active Active
- 2016-10-14 AU AU2016336868A patent/AU2016336868B2/en active Active
- 2016-10-14 DK DK16793764.8T patent/DK3362569T3/da active
- 2016-10-14 JP JP2018519323A patent/JP7018387B2/ja active Active
- 2016-10-14 WO PCT/EP2016/074644 patent/WO2017064222A1/en active Application Filing
- 2016-10-14 CA CA3001507A patent/CA3001507C/en active Active
- 2016-10-14 ES ES16793764T patent/ES2895901T3/es active Active
- 2016-10-14 US US15/768,301 patent/US11723922B2/en active Active
-
2021
- 2021-10-01 JP JP2021162481A patent/JP2022008805A/ja active Pending
-
2022
- 2022-07-14 AU AU2022205240A patent/AU2022205240A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022008805A (ja) | 2022-01-14 |
CA3001507C (en) | 2023-09-19 |
EP3362569B1 (en) | 2021-09-01 |
JP2018531016A (ja) | 2018-10-25 |
AU2016336868B2 (en) | 2022-04-14 |
CA3001507A1 (en) | 2017-04-20 |
AU2016336868A1 (en) | 2018-03-15 |
ES2895901T3 (es) | 2022-02-23 |
JP7018387B2 (ja) | 2022-02-10 |
US11723922B2 (en) | 2023-08-15 |
EP3362569A1 (en) | 2018-08-22 |
WO2017064222A1 (en) | 2017-04-20 |
US20180256645A1 (en) | 2018-09-13 |
AU2022205240A1 (en) | 2022-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL259017A (en) | Cancer cure is intended | |
DK3240801T3 (da) | Kombinationstumorimmunterapi | |
DK3289080T3 (da) | Genterapi til autosomalt dominante sygdomme | |
DK3294770T3 (da) | Terapeutiske og diagnostiske fremgangsmåder til cancer | |
DK3262066T4 (da) | Genterapi | |
DK3594238T3 (da) | Antistofsammensætninger til tumorbehandling | |
DK3212670T3 (da) | Kombinationsterapi mod cancer | |
DK3171929T3 (da) | Dosering til nervestimulation | |
DK3564252T3 (da) | Modificerede nukleotidlinkere | |
BR112017002511A2 (pt) | sistemas e métodos de almofada terapêutica | |
DK3107563T3 (da) | Glycomålrettede terapeutiske midler | |
SG11201605585SA (en) | Targeted therapy for small cell lung cancer | |
MA39483A (fr) | Agents thérapeutiques cibles | |
MA39481A (fr) | Thérapies ciblées | |
KR20180084772A (ko) | 암 치료를 위한 조합 치료법 | |
DK3102200T3 (da) | Terapeutisk forbindelse og sammensætning | |
DK3362569T3 (da) | Cxcr6-transducerede t-celler til målrettet tumorterapi | |
BR112018005409A2 (pt) | terapêutica de glicodirecionamento. | |
IL249019A0 (en) | Protein modifications at a specific site | |
GB201500463D0 (en) | Therapeutic molecules | |
GB201500461D0 (en) | Therapeutic molecules | |
DK3393478T3 (da) | Kombinationsterapi | |
DK3386997T3 (da) | Monomaleimid-funktionaliserede platinforbindelser til cancerterapi | |
KR20180084747A (ko) | Galgt2 유전자 치료 방법 및 물질 | |
DK3408265T3 (da) | Terapeutiske forbindelser |